{"title":"Improving care in lupus pregnancies: utility of educational tools to improve awareness.","authors":"Vijaya Prasanna Parimi,Laura Andreoli,Vinod Ravindran","doi":"10.1093/rheumatology/keaf491","DOIUrl":"https://doi.org/10.1093/rheumatology/keaf491","url":null,"abstract":"","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":"90 1","pages":""},"PeriodicalIF":5.5,"publicationDate":"2025-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145089874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
RheumatologyPub Date : 2025-09-14DOI: 10.1093/rheumatology/keaf493
Eirik Ikdahl
{"title":"Comment on: Risk of venous thromboembolism in people with rheumatoid arthritis: a population-based study in the UK.","authors":"Eirik Ikdahl","doi":"10.1093/rheumatology/keaf493","DOIUrl":"https://doi.org/10.1093/rheumatology/keaf493","url":null,"abstract":"","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145092474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Efficacy and safety of a millimetre wave medical device for pain neuromodulation in peripheral osteoarthritis: a crossover randomised trial.","authors":"Caroline Maindet,Joris Giai,Corentin Leroy,Marion Proust,Gilliane Lalami,Isabelle Boudry,Marlène Thiers,Jean-Luc Bosson,Laurent Grange","doi":"10.1093/rheumatology/keaf486","DOIUrl":"https://doi.org/10.1093/rheumatology/keaf486","url":null,"abstract":"OBJECTIVESTo manage osteoarthritis (OA)-related pain, current guidelines recommend a combination of non-pharmacological and pharmacological treatments. The objective of this study was to assess a millimetre-wave-emitting medical device (MD) for neuromodulation of pain in patients with peripheral OA.METHODSIn this monocentric, prospective, crossover, randomised controlled trial, 60 patients with peripheral OA affecting joints (ankle, knee, hip, shoulder, elbow, and fingers) and a pain score ≥ 4 on the Visual Analogue Scale (VAS) were recruited and randomly assigned to one of two crossover sequences. The primary outcome was self-assessed pain, while secondary outcomes included life and sleep quality.RESULTSOf the 60 patients included, 31 were randomly assigned to the OFF/ON sequence and 29 to the ON/OFF sequence. The baseline mean pain scores for the groups was 6.05 (SD = 1.36) and 6.31 (SD = 1.52) on the VAS, respectively. During the MD use period, the mean daily VAS pain score was 4.57 (SD = 2), compared with 5.32 (SD = 1.77) during the period without MD use. The mean paired difference between periods was 0.74 (SD = 1.77). This difference was statistically significant (p= 0.002). The corresponding effect size was 0.42. No carryover, sequence, or period effects were observed. Secondary outcomes related to quality of life and sleep quality showed significant improvement with MD use. No serious adverse events were reported.CONCLUSIONIn patients with peripheral OA, regular use of this MD significantly reduced in pain (VAS), improved both quality of life (EQ5D-5L) and sleep quality (VAS). Future research should focus on individualised benefit-risk balance, incorporating patient preferences.CLINICAL TRIALS REGISTRATIONClinicalTrials.gov; NCT04590079.","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":"7 1","pages":""},"PeriodicalIF":5.5,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145089879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
RheumatologyPub Date : 2025-09-13DOI: 10.1093/rheumatology/keaf494
Mark D Russell, Katie Bechman, Mark Gibson, Victoria Basey, Michael Mclean, Saqib Rana, Anna Barkaway, Simon de Lusignan, Maya H Buch, James B Galloway
{"title":"Comment on: Risk of venous thromboembolism in people with rheumatoid arthritis: a population-based study in the UK: reply.","authors":"Mark D Russell, Katie Bechman, Mark Gibson, Victoria Basey, Michael Mclean, Saqib Rana, Anna Barkaway, Simon de Lusignan, Maya H Buch, James B Galloway","doi":"10.1093/rheumatology/keaf494","DOIUrl":"https://doi.org/10.1093/rheumatology/keaf494","url":null,"abstract":"","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145092419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
RheumatologyPub Date : 2025-09-11DOI: 10.1093/rheumatology/keaf483
Nikolaos Papazoglou, Vassiliki Poulia, Elisavet Michailidou, George V Papatheodoridis, Petros P Sfikakis, Maria G Tektonidou
{"title":"Sustained cardiovascular risk factor control is associated with reduced metabolic dysfunction-associated steatotic liver disease risk in SLE.","authors":"Nikolaos Papazoglou, Vassiliki Poulia, Elisavet Michailidou, George V Papatheodoridis, Petros P Sfikakis, Maria G Tektonidou","doi":"10.1093/rheumatology/keaf483","DOIUrl":"https://doi.org/10.1093/rheumatology/keaf483","url":null,"abstract":"<p><strong>Objectives: </strong>Patients with SLE have a higher prevalence of cardiometabolic risk factors, metabolic syndrome and cardiovascular disease than the general population. The metabolic dysfunction-associated steatotic liver disease (MASLD), a new term for non-alcohol-related fatty liver disease, has been recognized as an independent predictor of cardiovascular events in the general population. However, the prevalence and associations of MASLD in SLE are uncertain. We aimed to investigate the potential association between MASLD and traditional and disease-related cardiovascular risk factors (CVRFs) in SLE.</p><p><strong>Methods: </strong>Patients with SLE and age- and sex-matched healthy control (HCs) who completed a 10-year carotid/femoral ultrasound follow-up examination were invited to undergo transient liver elastography (TEA) to assess MASLD prevalence based on international consensus criteria. Multivariate regression models examined associations between MASLD and the CVRF burden in past 10 years, including traditional and disease-related CVRFs, and atherosclerotic plaque progression.</p><p><strong>Results: </strong>TEA was performed in 77 SLE patients (median age: 53 years) and 45 age/sex-matched HCs with 10-year follow-up; 40% of patients and 44% of HCs met criteria for MASLD. In SLE, MASLD risk was reduced by 55% (odds ratio [OR]: 0.45, P = 0.021) for each additional sustainedly achieved traditional CVRF target (blood pressure, lipids, smoking, physical activity, or body weight). Patients with femoral plaque progression and consistent IgG anti-beta2glycoprotein I antibody positivity over the past 10 years had a 3.6-fold (OR: 3.62, P = 0.047) and 6.6-fold (OR: 6.58, P = 0.021) higher risk for MASLD, respectively.</p><p><strong>Conclusion: </strong>Femoral plaque progression and persistent IgG anti-beta2 glycoprotein I antibody positivity are independently associated with MASLD in SLE, while MASLD risk is halved for each additional CVRF target sustainedly attained.</p>","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145113840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
RheumatologyPub Date : 2025-09-11DOI: 10.1093/rheumatology/keaf467
Bhaskar Dasgupta,Christian Dejaco,Kornelis van der Geest,Humphrey Hodgson,Kenneth J Warrington
{"title":"Should all polymyalgia rheumatica be referred to rheumatology? A call for unified stratified specialist care of the GCA-PMR spectrum.","authors":"Bhaskar Dasgupta,Christian Dejaco,Kornelis van der Geest,Humphrey Hodgson,Kenneth J Warrington","doi":"10.1093/rheumatology/keaf467","DOIUrl":"https://doi.org/10.1093/rheumatology/keaf467","url":null,"abstract":"","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":"56 1","pages":""},"PeriodicalIF":5.5,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145089881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
RheumatologyPub Date : 2025-09-11DOI: 10.1093/rheumatology/keaf482
Fadi Kharouf,JuanPablo DiazMartinez,Pankti Mehta,Dafna D Gladman,Laura P Whittall Garcia,Zahi Touma
{"title":"Is antimalarial use associated with a reduced risk of LN in patients with SLE? Results from an inception cohort-based study.","authors":"Fadi Kharouf,JuanPablo DiazMartinez,Pankti Mehta,Dafna D Gladman,Laura P Whittall Garcia,Zahi Touma","doi":"10.1093/rheumatology/keaf482","DOIUrl":"https://doi.org/10.1093/rheumatology/keaf482","url":null,"abstract":"OBJECTIVESAntimalarials are a cornerstone in managing SLE and are associated with multiple favourable disease outcomes. This study explored whether antimalarial use is associated with a reduced risk of incident LN in SLE patients.METHODSWe included SLE patients from an inception cohort with no prior history of LN, followed prospectively at regular intervals. The relationship between the exposure (cumulative duration of antimalarial exposure in years) and the outcome (development of LN, as indicated by new-onset proteinuria attributed to lupus activity by clinical judgement and recorded in the SLEDAI-2K sheet) was characterized using a time-dependent univariable Cox proportional hazards model to estimate the overall effect. Adjusted multivariable Cox regression was also employed to estimate the risk of LN, incorporating clinically relevant variables.RESULTSThe study included 674 inception SLE patients, with a median baseline age of 33.6 years (interquartile range [IQR]: 24.9-45.4). One hundred and fifty-four patients (22.8%) developed SLE-related new-onset proteinuria, indicating LN, with a median time to event of 3.6 years [IQR: 0.9-8.8]. Cumulative duration of antimalarial exposure was not significantly associated with a lower risk of LN, either in the unadjusted univariable model estimating the overall effect (hazard ratio [HR]: 0.98; 95% CI: 0.94-1.02, P = 0.25) or in the adjusted multivariable model (HR: 0.96; 95% CI: 0.92-1.00, P = 0.08). This finding was also corroborated in a sensitivity analysis of patients with serologically active SLE (HR: 0.97; 95% CI: 0.92-1.02).CONCLUSIONAntimalarial use is not significantly associated with a reduced risk of incident LN in SLE patients.","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":"77 1","pages":""},"PeriodicalIF":5.5,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145089882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}